Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.
Elliott
A M
AM
Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA.
Foster
S D
SD
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D013828:Thioacetazone / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D013828:Thioacetazone